Navigation Links
Genome analysis of brain tumors showing the way to new treatment strategies
Date:7/26/2012

Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma.

In order to find new target structures for more gentle treatment methods, cancer researchers are systematically analyzing all changes in the genetic material of such tumors. This is the mission of the PedBrain consortium, which was launched in 2010 as the first German part in the International Cancer Genome Consortium (ICGC). The PedBrain Tumor network, which is coordinated by Professor Peter Lichter of DKFZ and Professor Roland Eils (DKFZ and Heidelberg University), has now published, jointly with numerous collaboration partners, an evaluation of the first 125 genome analyses of medulloblastomas.

"We can already see great differences in the genomes of medulloblastomas from one patient to the next," says Peter Lichter. "But we have also identified a number of frequent and characteristic genomic alterations that may lead the way to developing new methods of diagnosis and treatment."

Brain tumors with four sets of chromosomes are particularly aggressive

A high percentage of medulloblastomas particularly among those with very malignant progression has four sets of chromosomes instead of two as normal. Medulloblastomas are classified into four groups according to aggressiveness. In the study, about half of tumors belonging to groups 3 and 4, which are very difficult to treat, were found to have this aberration. "It is not proven that the extra chromosomes cause cancer. But it is certain that they occur at a very early stage of the cancerous process," Lichter explains.

Cells with four sets of chromosomes have been found in several types of cancer. However, this genomic aberration also offers a chance of specifically attacking tumors. At the German Cancer Research Center (DKFZ), researchers collaborating with Bayer Healthcare are currently working to develop an agent which specifically inhibits the growth of cells with more than two sets of chromosomes.

About one third of individual mutations in medulloblastoma are found in genes that play a part in what are called epigenetic modifications. "This finding shows once more that drugs influencing such modifications will become increasingly important in cancer treatment," says Professor Dr. Stefan Pfister, a pediatrician and molecular biologist. DKFZ and Heidelberg University Hospital are already testing such promising substances to treat specific pediatric tumors.

The total number of genomic alterations in medulloblastoma increases with the age of patients. "Although many scientists have supposed that there is such a correlation, it has never been documented before," Stefan Pfister explains. "We suspect, however, that the foundation for medulloblastoma is laid already during embryonic development."

For the first time, the PedBrain researchers have also found what are called fusion genes in medulloblastoma. Such genes are formed when, due to genetic accidents, cancer-promoting genes are fused together and new proteins occur as a result. Such fusion genes cause a number of cancers such as chronic myelogenous leukemia (CML). For this cancer, researchers have succeeded in developing a very effective drug against the BCR-ABL fusion gene, which is highly specific for leukemia cells.

"Along with a multitude of individually occurring mutations, we were able to define a number of typical groups of mutations, which will show us the way to new strategies of fighting medulloblastoma", says Peter Lichter to sum up. "Given the genetic complexity and heterogeneity of this tumor type, a useful future approach would be to analyze the tumor genome in each affected child in order to identify the most promising treatment."

International collaboration to analyze tumor genomes

The International Cancer Genome Consortium (ICGC), a network of scientists from currently 14 countries, aims to obtain a comprehensive description of genomic and epigenomic changes in all relevant cancers. Germany participates with the PedBrain Tumor project to analyze pediatric brain tumors (medulloblastoma, which in Germany affects approximately 100 children each year; and pilocytic astrocytoma, which is diagnosed in about 200 children each year). As part of the PedBrain Tumor project, 300 tumor samples of each tumor type will be analyzed, along with the same number of healthy samples from the same patients in order to identify changes that are cancer-specific.

The PedBrain Tumor network consists of researchers from seven institutes led by project coordinator Peter Lichter of DKFZ. Alongside DKFZ, participating project partners in Heidelberg are: the National Center for Tumor Diseases (NCT), Heidelberg University and the University Hospital, and the European Molecular Biology Laboratory (EMBL). In addition, scientists from Dsseldorf University Hospital and the Max Planck Institute for Molecular Genetics in Berlin have taken on tasks within the network project.

PedBrain Tumor was supported by the German Cancer Aid (Deutsche Krebshilfe) with funds of eight million euros and has been funded by the Federal Ministy of Education and Research (BMBF) since 1 July 2012 with another seven million euros.

Furthermore, the PedBrain researchers from DKFZ have contributed results of their medulloblastoma analyses to another two publications in the current issue of Nature. Besides the PedBrain Tumor network, scientists from DKFZ are collaborating in the genome analysis of early prostate cancer (coordination: DKFZ and University Medical Center Hamburg-Eppendorf) and B cell lymphomas (coordination: University of Kiel).


'/>"/>
Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Mayo Clinic launches whole genome breast cancer study
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Control of gene expression: Histone occupancy in your genome
4. Scientists Map Melanomas Genome
5. Genomes show how Staph bacteria gain resistance to last-line drug
6. Scientists Map the Tomatos Genome
7. Entire Genome of Human Fetus Deciphered
8. Bonobo Genome Sheds Light on Their Links to Chimps, Humans
9. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
10. Genome-wide analysis shows previously undetected abnormalities in parents of affected children
11. New Stanford method enables sequencing of fetal genomes using only maternal blood sample
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology: